

## SeQuent announced launch of Citramox<sup>®</sup> LA in EU

**Mumbai, December 10, 2020**

SeQuent Scientific Limited (SeQuent), announced launch of Citramox<sup>®</sup> LA 150 mg/ml Suspension Injection for Cattle and Pigs in 10 European countries, including the key markets of Western Europe. The product has recently received approval through its Spanish subsidiary Laboratorios Karizoo, S.A., and will be the first Long-Acting injectable to be offered by SeQuent in Europe.

This new approval for SeQuent builds on the recent approvals of Tulazzin<sup>®</sup> (Tulathromycin) and Halofusol<sup>®</sup> (Halofuginone) in Europe. All these approvals have been received within 12 months of filing, which reflects on SeQuent's growing strengths in introducing new products for the regulated markets.

Citramox<sup>®</sup> is the first generic version of Vetrिमoxin LA (Innovator: Ceva Animal Health Inc) to be approved and launched in Europe, which is an effective antibiotic indicated for the treatment of respiratory infections caused by Mannheimia haemolytica and Pasteurella multocida susceptible to amoxicillin in cattle and pigs. Citramox<sup>®</sup> formulation has good homogeneity and high fluidity profile, which along with its user-friendly plastic vial packaging and withdrawal times offers superior value to farmers.

The market size in Europe for Amoxicillin Long-Acting products is estimated to be ~€ 20 Million.

### **About SeQuent Scientific Limited**

SeQuent Scientific Limited (BSE-512529, NSE-SEQUENT) headquartered in Mumbai, India with a global footprint, operates in the domains of Animal Health (Alivira) and Analytical Services. SeQuent has eight manufacturing facilities based in India, Spain, Germany, Brazil and Turkey with approvals from global regulatory bodies including USFDA, EUGMP, WHO, TGA among others. Its Vizag facility is India's first and only USFDA approved facility for veterinary APIs.

---

---

**For details, feel free to contact:**

**Tushar Mistry**

Chief Financial Officer Tel: +91 22 4111 4717  
[tushar.m@sequent.in](mailto:tushar.m@sequent.in)

**Diwakar Pingle**

Christensen Investor Relations Tel : +91 22 4215 0210  
[dpingle@christensenir.com](mailto:dpingle@christensenir.com)

**Abhishek Singhal**

Investor Relations Consultants [abhishek.s@sequent.in](mailto:abhishek.s@sequent.in)

**Registered Office**

301/A, 'Dosti Pinnacle', Plot No. E7, Road No. 22,  
Wagle Industrial Area, Thane (W), Maharashtra, India CIN:

L99999MH1985PLC036685

BSE Code:512529 | NSE: SEQUENT

ISIN: INE807F01027 | REUTERS: EQU.BO

Websites: [www.sequent.in](http://www.sequent.in)

*Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward- looking statements. SeQuent Scientific Ltd. will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.*